glp 1 microdosing for autoimmune The Role of GLP-1s in Metabolic Health PLUS Potential Benefits of Disease and Inflammation: A Functional Medicine Perspective — Altheda Health What Is Microdosing GLP-1s Like

Those ovaries are retired, so that's the brain starting to yell at the ovaries

DAlessio

Explore key insights from an industry insider: #Pharma #RegulatoryAffairs #GLP1 #DrugDevelopment #FDA #Generics #CMC How to develop generic GLP-1 injections: Insights from an FDA reviewer ELIQUENT Life Sciences Expert Vincent Li, Ph.D., former FDA CMC reviewer, dives deep into the regulatory and scientific challenges of developing generic GLP-1 peptide injections

In a study of 3,731 patients assigned to take either liraglutide or placebo, 63.2% of patients taking liraglutide lost at least 5% of their body weight and 33.1% of patients lost at least 10% of their body weight

Approved indications for GLP-1s: Cardiovascular disease Chronic kidney disease Obesity Sleep apnea Type 2 diabetes Metabolic dysfunction-associated steatohepatitis (MASH) Potential future indications: (indications with asterisks have already been investigated in randomized clinical trials) Substance use disorders (alcohol, tobacco) Alzheimers Parkinsons Cancer prevention Diabetes prevention* Diabetic retinopathy Heart failure* Osteoarthritis* Peripheral artery disease* Polycystic ovarian syndrome Psoriasis When I was at the ADAs 85th Scientific Sessions this year, what was quite apparent was just how quickly the field has progressed beyond GLP-1s

The development of new GLP-1RA therapies requires post-marketing safety evaluations and real-world evidence to identify and address potential risks